BEDFORD, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to ...
Life Molecular Imaging Limited, a radiopharmaceutical company recently acquired by US-based Lantheus, has opened a fully customised 1,474 sq ft office at Arena Offices’ Number 25 centre in Segensworth ...
BOSTON, Oct. 7, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, and SOFIE Biosciences (SOFIE), a national US manufacturer and developer of PET radiopharmaceuticals, announce ...
BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd.
[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received ...
Fast Track Designation Granted for use in patients being evaluated for Alzheimer's Disease, Progressive Supranuclear Palsy, or Corticobasal Degeneration BOSTON, Aug. 28, 2024 /PRNewswire/ -- Life ...
BOSTON, April 24, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a world-class contract development and manufacturing organization (CDMO) and ...
BOSTON, Aug. 20, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI), a Lantheus company, dedicated to developing and offering novel PET radiopharmaceuticals, has expanded its manufacturing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results